Last reviewed · How we verify

Tezepelumab (AI) — Competitive Intelligence Brief

Tezepelumab (AI) (Tezepelumab (AI)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: IL-33 antagonist. Area: Respiratory.

phase 3 IL-33 antagonist IL-33 Respiratory Biologic Live · refreshed every 30 min

Target snapshot

Tezepelumab (AI) (Tezepelumab (AI)) — AstraZeneca. Tezepelumab is an interleukin-33 (IL-33) antagonist that blocks the activity of IL-33, a cytokine involved in the development of asthma.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Tezepelumab (AI) TARGET Tezepelumab (AI) AstraZeneca phase 3 IL-33 antagonist IL-33

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (IL-33 antagonist class)

  1. AstraZeneca · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tezepelumab (AI) — Competitive Intelligence Brief. https://druglandscape.com/ci/tezepelumab-ai. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: